Entrada Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio9.33
P/S Ratio2.903.90
P/B Ratio1.432.081.991.79
Price/Tangible Book1.432.081.991.79
Price/FCF3.75
Price/OCF3.60
Enterprise Value Ratios
EV/Revenue1.061.69
EV/EBITDA4.41
EV/EBIT4.77
EV/FCF1.63
Profitability & Returns
Return on Equity (ROE)0.20%-0.03%-0.37%-0.30%-0.94%
Return on Assets (ROA)0.06%-0.01%-0.22%-0.18%-0.54%
Return on Invested Capital (ROIC)3.50%0.42%-2.33%-11.65%-92.43%
Return on Capital Employed (ROCE)0.10%-0.01%-0.42%-0.17%-0.66%
Leverage & Solvency Ratios
Debt/Equity0.140.280.12
Debt/EBITDA0.924.68
Debt/FCF0.51
Liquidity Ratios
Current Ratio11.142.339.5544.4611.89
Quick Ratio10.782.268.6243.3211.62
Efficiency Ratios
Asset Turnover0.420.36
Yield & Distribution Ratios
Earnings Yield0.11%-0.01%-0.22%-0.10%
FCF Yield-0.07%0.27%-0.23%-0.10%
Buyback Yield-0.18%-0.06%-3.99%-4.67%-0.18%